EY Report Highlights Key Trends in US MA Activity for March 2026 Provectus Biopharmaceuticals Issues Going Concern Warning Following Q1 2026 Loss Sarepta SRPT Delivers Q1 2026 Beat EPS 288 vs 101 Expected